GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Novonesis expects results from weight-loss drug supplement study in 2027Ocado confirms Denmark's nemlig as latest European partnerGerman prosecutors file charges in tax fraud case against four former Commerzbank staffFrance fines Boohoo €2.3 million over deceptive discounts on websiteFTSE 100 falls as JD Sports tumbles on profit warningSterling hits six-month high against fading dollarTanker off Yemen boarded by armed people, diverted towards Somalia, UKMTO saysRussian strikes kill 16 in Ukraine, Zelenskiy says lack of Patriots costs livesTrump warns of economic consequences for any country that supports IranSerbia turns to Russia to help fight wildfiresOil hits 3-week high on Middle East supply concerns amid war impasseExclusive-More than 150 Polymarket wallets may have traded on military secrets, research finds

Latest Banking & Finance News & Analysis

Thursday, 20 August 2026 · Global Edition

Featured

Novonesis expects results from weight-loss drug supplement study in 2027

Finance

Novonesis expects results from weight-loss drug supplement study in 2027

By Vera Dvorakova and Jesus Calero Aug 20 (Reuters) - Danish biosolutions maker Novonesis expects results in the second half of 2027 from research with Novo Nordisk into whether microbiome supplements

Global Banking & Finance Review

Image for Novonesis expects results from weight-loss drug supplement study in 2027

Breaking

See all →

Banking

More stories →
Global Banking & Finance Awards 2026 — Call for entries, nominate your organization

Technology

See them all →

Finance Spotlight

See all →

More News

See all →